<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01476774</url>
  </required_header>
  <id_info>
    <org_study_id>BP08-CN-001</org_study_id>
    <nct_id>NCT01476774</nct_id>
  </id_info>
  <brief_title>NORSPAN Transdermal Patches Phase III Study In Non-Cancer Pain</brief_title>
  <official_title>NORSPAN Transdermal Patches Phase III Study In Non-Cancer Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma (China) Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma (China) Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multiple-dose, double-blind, double-dummy, active-control, parallel-group,
      multi-center, safety and efficacy study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary Efficacy Variable is the change of Pain Intensity (Patients Visual Analogue Scale) from baseline</measure>
    <time_frame>11 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>Disease (or Disorder); Intervertebral Disc, With Myelopathy (Manifestation)</condition>
  <arm_group>
    <arm_group_label>Buprenorphine Transdermal System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol CR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine Transdermal System</intervention_name>
    <description>Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.
maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control .</description>
    <arm_group_label>Tramadol CR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine Transdermal System</intervention_name>
    <description>Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.
maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control .</description>
    <arm_group_label>Buprenorphine Transdermal System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females age are ≥20 ,≤80 years.

          -  Clinical diagnosis of musculoskeletal pain for 4 weeks or longer with non-malignant
             pain etiology at Visit 1.

          -  Subject is a current user of NSAIDS or paracetamol and reports a history of
             insufficient therapeutic benefit in musculoskeletal pain.

          -  Subjects must record an 'average pain over the last week at study institution' score
             at primary pain site of ≥ 4 on an 11-point numerical pain rating scale.

          -  Subjects must be able to understands the study procedures and assessment, and agree to
             participate in the study by giving written informed consent.

        Exclusion Criteria:

          -  Subjects who have been taking long-acting or short-acting opioid analgesic
             formulations within the last 4 weeks.

          -  Subjects who have a current chronic disease(s) or who have a past history and high
             possibilities to relapse, in addition to their musculoskeletal pain, requiring
             frequent analgesic therapy.

          -  Subjects with clinically unstable respiratory disease, dysfunction of the biliary
             tract, thyroid disease, adrenal cortical insufficiency, prostatic hypertrophy
             requiring intervention or renal artery stenosis.

          -  Subject who have a past history of malignant neoplasm including leukemia and lymphoma.

          -  Subjects with clinically unstable, active or symptomatic heart disease.

          -  Subjects who have psychiatric disorder, uncontrolled seizures or convulsive disorder
             and so on.

          -  Subjects who have a current or past (within 5 years) history of substance or alcohol
             abuse, or subjects who give a positive result in drug abuse test during the Screening
             Period.

          -  Subjects scheduled for therapies within the study period which might effect study
             assessment.

          -  Females who are pregnant, lactating or have a possibility of being pregnant.

          -  Subjects with values &gt; 2 times the upper limit of normal for AST or ALT or total
             bilirubin at visit 1 or who have severe impaired liver function.

          -  Subjects with serum creatinine &gt; 2 mg/dL at Visit 1 or who have severe impaired renal
             function.

          -  Subjects with serum potassium &lt; 3.5 mEq/L at Visit 1.

          -  Subjects receiving hypnotics or other central nervous system (CNS) depressants.

          -  Subjects receiving monoamine oxidase inhibitor (MAOI) within 2 weeks before screening.

          -  Subjects who have a history of supersensitivity to study drug.

          -  Known intolerance to and/or lack of effect of tramadol.

          -  Subjects who participated in a clinical research study within 1 month of study entry.

          -  Subjects who participated previously in a BTDS study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mundipharma China Ltd.</last_name>
    <role>Study Chair</role>
    <affiliation>Mundipharma China Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site:Peking Union Medical Hospital (PUMC)</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2011</study_first_submitted>
  <study_first_submitted_qc>November 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>July 7, 2015</last_update_submitted>
  <last_update_submitted_qc>July 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Diseases</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Intervertebral Disc Displacement</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

